Clinical features, treatment, and prognosis of nivolumab induced immune encephalitis [0.03%]
纳武单抗引起免疫性脑炎的临床特征，治疗和预后
Zhaoquan Wu,Haibo Lei,Ronghui Li et al.
Zhaoquan Wu et al.
Immune encephalitis (IE) is an immune-mediated adverse events (irAEs) linked to nivolumab therapy, and its clinical characteristics remain unclear. This study aimed to analyze the clinical patterns of nivolumab-induced IE to inform diagnosi...
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma [0.03%]
首个人体，一期剂量递增研究的SL-279252，一种六聚物PD1-Fc-OX40L融合蛋白，在晚期实体瘤和淋巴瘤患者中的应用
Melissa Johnson,David Hong,Irene Braña et al.
Melissa Johnson et al.
SL-279252 is a bifunctional hexameric fusion protein adjoining the extracellular domains of PD-1 and OX40L via an inert IgG4 derived Fc domain. A Phase 1 dose escalation study was conducted in patients (pts) with advanced solid tumors or ly...
From development to clinical success: the journey of established and next-generation BTK inhibitors [0.03%]
从研发到临床成功：已上市与下一代BTK抑制剂的历程
Shivani Gupta,Arpit Sharma,Alok Shukla et al.
Shivani Gupta et al.
Over the past decade, Bruton's tyrosine kinase (BTK) has emerged as a pivotal therapeutic target for B-cell malignancies and autoimmune diseases, given its essential role in B-cell development and function. Dysregulation of BTK signalling i...
Retrospective analysis of clinical features of nivolumab-induced immune-related pancreatitis [0.03%]
尼伏鲁单抗引起免疫介导胰腺炎的临床特征的回顾分析
Yong Pan,Wei Li,Zhaoquan Wu et al.
Yong Pan et al.
To study the clinical features of nivolumab-induced immune-related pancreatitis and to provide evidence for its recognition and treatment. Cases of nivolumab-induced pancreatitis were collected by searching Chinese and English databases unt...
A novel anti-HER2/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs [0.03%]
新型抗HER2/EGFR双特异性抗体药物偶联物表现出有前景的抗肿瘤功效并克服了对HER2或EGFR靶向ADC的耐药性
Huoying Huang,Yuxin Zhou,Chengzhang Shang et al.
Huoying Huang et al.
HER2 and EGFR are frequently co-expressed in various tumors. While antibody-drug conjugates (ADCs) targeting HER2, such as T-DM1 and T-Dxd, have shown remarkable antitumor effects in clinical responses, their effectiveness is constrained by...
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study [0.03%]
校正内容：Selinexor联合卡铂和紫杉醇治疗晚期实体瘤患者：单中心、多组别Ⅰb期研究结果
Kyaw Z Thein,Daniel D Karp,Apostolia Tsimberidou et al.
Kyaw Z Thein et al.
Published Erratum
Investigational new drugs. 2025 Feb 20. DOI:10.1007/s10637-024-01493-5 2025
A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors [0.03%]
RMX1002，一种选择性的E型前列腺素受体4拮抗剂，作为单一疗法和与抗PD-1抗体组合在晚期实体瘤中的一期剂量递增和扩展研究
Dan Liu,Jifang Gong,Jian Zhang et al.
Dan Liu et al.
RMX1002 (grapiprant) is a selective E-type prostanoid receptor 4 (EP4) antagonist and a promising candidate for cancer therapy, potentially enhancing anti-tumor immune responses. This study aimed to evaluate the safety, pharmacokinetics, ph...
Helin Li,Xuelian Shen,Yu Chu et al.
Helin Li et al.
Research on prodrug technology has opened new avenues for site-directed chemotherapy rather than systemic chemotherapy. This distinctive strategy allows drug delivery to be activated by light-, irradiation-, or ultrasound (US)-tunable chemi...
Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity [0.03%]
PARP抑制剂对铂类药物诱导的心脏毒性的保护作用
Jae Hyun Kim,Ja-Young Han,Jae-Hee Kwon et al.
Jae Hyun Kim et al.
Poly(ADP-ribose) polymerase (PARP) inhibitors may have cardioprotective properties. This study aimed to evaluate the potential cardioprotective effects of PARP inhibitors in patients with epithelial ovarian cancer treated with platinum-base...
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response [0.03%]
KRAS G12C抑制剂在治疗耐药结直肠癌中的进展及药物耐受性应对策略
Peiyuan Yang,Yongchao Li
Peiyuan Yang
Colorectal cancer is the third most prevalent cancer in the world. Early screening and detection of tumours, active surgical radical treatment, postoperative adjuvant chemotherapy, targeted therapy, and immunotherapy are performed based on ...